Denosumab: New Horizons in the Treatment of Osteoporosis

Nursing for Women's Health

Volumn 15, Issue 3, 2011, Pages 249-252

  Wilton, Jeanne M ^a  

^a Wheaton Franciscan Healthcare   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79958845373     PISSN: 17514851     EISSN: 1751486X     Source Type: Journal    
DOI: 10.1111/j.1751-486X.2011.01641.x     Document Type: Article

References (8)

1. Amgen Manufacturing Limited, a subsidiary of Amgen Inc. (2010). Product information for Prolia. Thousand Oaks, CA: Author.
2. Anonymous. (2010). New drug: Prolia (denosumab). Pharmacist's Letter/Prescriber's Letter, 26 (260803), 1-5.
3. Barclay, L. (2011). US Task Force releases updated osteoporosis screening recommendations. Annals of Internal Medicine. Retrieved from
4. Brown, J. P., Prince, R. L., Deal, D., Recker, R. R., Kiel, D. P., de Gregorio, L. H., et al. (2009). Comparison of effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: A randomized, blinded, phase 3 trial. Journal of Bone Mineral Research, 24 (1), 153-161.
5. Cummings, S. R., San Martin, J., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., et al. (2009). Denosumab for prevention of fractures in postmenopausal women with osteoporosis. New England Journal of Medicine, 361, 756-765.
6. National Osteoporosis Foundation. (2011). Why bone health is important. Retrieved from
7. North American Menopause Society. (2010). Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause, 17, 25-54.
8. Warner Chilcott. (2010). Product information for Atelvia. North Norwich, NY: Author.